Company Insights

PBYI customer relationships

Explore interactive graphBrowse insights index
PBYI customer relationship map

Puma Biotechnology (PBYI): Commercial Relationships and What They Mean for Revenue Risk

Puma Biotechnology commercializes NERLYNX as its core product and monetizes through two primary routes: direct U.S. specialty sales and royalty/sub-license income from international partners. Domestically, Puma sells to a concentrated set of specialty pharmacies and distributors that resell directly to patients; internationally, the company uses exclusive sub-licenses that convert partner sales into royalty streams. For investors evaluating counterparty exposure, the structure delivers high gross margins on product sales but concentrates counterparty risk across a small number of large pharmacy and distribution partners. For more granular customer intelligence, visit https://nullexposure.com/.

How Puma’s commercial model works in practice

Puma runs a dual-channel commercial model with clear implications for contracting posture, concentration and criticality.

  • Contracting posture — licensing plus distribution. Puma executes exclusive sub-license agreements to commercialize NERLYNX outside the U.S. and sells into a limited network of specialty pharmacies and specialty distributors inside the U.S., reflecting a hybrid seller/distributor/licensee posture documented in Puma’s filings.
  • Concentration — revenue dependent on a few large counterparties. The company discloses that in 2024 four customers accounted for roughly 28.4%, 18.8%, 14.1% and 12.3% of product revenue respectively, a structural concentration that elevates counterparty and collections risk.
  • Criticality — specialty pharmacies are core to patient access. Puma’s model depends on specialty pharmacies and distributors to deliver NERLYNX directly to patients; these partners are critical resellers rather than peripheral channels.
  • Geographic maturity — global footprint via sub‑licensees. Puma has established licensing relationships across NA, EMEA, APAC and LATAM through exclusive sub-licenses, producing both product revenue and recurring royalty cash flows, with a notable royalty concentration tied to China sales.
  • Relationship stage — active commercialization. Puma’s commercial activity is mature and active: NERLYNX is the primary revenue driver and the company maintains a direct U.S. specialty sales force alongside the reseller network.

These characteristics drive the investment trade-off: high-margin, predictable royalties combined with single-product concentration and a narrow set of distribution counterparties.

Customer relationships on record: who Puma sells to and partners with

Below I cover every named counterparty reflected in Puma’s publicly available customer and news excerpts.

  • Optum — Puma lists Optum as one of the specialty pharmacies in its U.S. specialty pharmacy network that sells directly to patients, indicating Optum acts as a downstream pharmacy/reseller for NERLYNX under Puma’s commercial distribution model. Source: Puma’s 2024 Form 10‑K (FY2024).

  • Accredo — Accredo is named as a member of the specialty pharmacy network that receives product for direct-to-patient fulfillment, establishing it as a material U.S. channel partner in Puma’s distribution mix. Source: Puma’s 2024 Form 10‑K (FY2024).

  • Biologics — Biologics is included among specialty pharmacies that dispense NERLYNX directly to patients, reinforcing that Puma routes U.S. product revenue through a limited set of specialty pharmacy providers. Source: Puma’s 2024 Form 10‑K (FY2024).

  • Acaria Health — Acaria Health is identified as part of the specialty pharmacy network that sells directly to patients, confirming its role as a reseller channel for Puma’s U.S. commercialization. Source: Puma’s 2024 Form 10‑K (FY2024).

  • ONCO 360 — ONCO 360 appears in Puma’s list of specialty pharmacies, indicating its place in Puma’s U.S. fulfillment network for NERLYNX and contributing to the concentrated customer base referenced in filings. Source: Puma’s 2024 Form 10‑K (FY2024).

  • CVS (CVS) — CVS is explicitly named in Puma’s specialty pharmacy network and is associated with the inferred ticker CVS; CVS functions as a major chain pharmacy/reseller in Puma’s U.S. distribution footprint. Source: Puma’s 2024 Form 10‑K (FY2024).

  • Pierre Fab — Puma discloses that Q3 2024 royalty revenue included sales to China by its offshore partner Pierre Fab, establishing Pierre Fab as an international sub-licensee driving APAC/China royalty income. Source: Q3 2025 earnings call transcript reporting Q3 2024 royalty composition (InsiderMonkey).

Each of these relationships is documented in Puma’s public disclosures or contemporaneous earnings commentary and collectively defines the company’s revenue channels: a narrow U.S. reseller network and a set of international licensees producing royalties.

What these relationships imply for revenue risk and upside

Puma’s commercial architecture yields a clear set of investment implications.

  • Revenue concentration is the dominant risk vector. With four customers representing roughly 73.6% of product revenue (sum of the disclosed percentages), a single large counterparty disruption would materially affect top-line performance and working capital. This is a company-level signal from Puma’s 2024 disclosures.

  • Distribution partners are critical operational nodes. Specialty pharmacies such as CVS, Optum and Accredo are not optional channels; they are necessary for patient access and collections, increasing operational leverage to those counterparties.

  • International royalties diversify cash flow but introduce partnership and regional exposure. Sub-licensees like Pierre Fab convert overseas commercialization into royalty streams, shifting execution risk to local partners while creating APAC/China concentration for royalty receipts.

  • Contractual mix blends licensing and reseller sales. Puma’s use of exclusive sub-licenses outside the U.S. and direct/distribution sales inside the U.S. establishes a mixed contracting posture: recurring royalties versus transactional product sales, each with different margin and credit dynamics.

For investors tracking counterparty exposures or evaluating credit and commercial risk, these dimensions are actionable. For deeper customer-level signals and monitoring of relationship changes, visit https://nullexposure.com/.

Investor takeaways and recommended next steps

  • Positive: Puma’s model creates high gross margin product revenue and recurring royalty upside through international sub-licensees; its direct U.S. specialty sales force supports market penetration for NERLYNX.
  • Negative: High customer concentration and reliance on a handful of specialty pharmacies create material counterparty and collections risk; international royalties concentrate exposure in APAC/China via partners like Pierre Fab.
  • Actionable next steps: Monitor quarterly disclosures for shifts in the identity or revenue share of the top four customers, watch royalty patterns from APAC partners, and track any new sub-license agreements expanding EMEA/LATAM reach.

For investor teams and commercial operators who want ongoing visibility into Puma’s counterparty landscape and to receive alerts when partner footprints change, explore full monitoring options at https://nullexposure.com/.